Evolus, Inc. (EOLS) Market Cap & Valuation Ratios
Evolus, Inc. (EOLS) has a market cap of $463.0M and a price-to-sales ratio of 1.5, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
EOLSEvolus, Inc.Follow EOLS — free
—
Price chart with a free account
- Market cap
- 463.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
drug manufacturers - specialty & generic · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| EOLS | 0.5 | — | 1.8 | — | -4.7% | +14% | -6% | -26% |
| HROW | 1.1 | — | 4.6 | — | 0.5% | +21% | -1.0% | -2% |
| COLL | 0.7 | — | 2.1 | 4.4 | — | +14% | 19% | 9% |
| IRWD | 0.6 | 4.5 | 1.3 | 2.1 | — | +26% | 60% | — |
| AQST | 0.5 | — | 8.4 | — | -9.2% | +23% | -98% | — |
| TLRY | 0.4 | — | 0.4 | — | — | +16% | -9% | -6% |
| EBS | 0.3 | — | 1.0 | 26.8 | — | -10% | -9% | -8% |
| ANIK | 0.3 | — | 2.1 | 496.5 | 0.2% | +5% | -4% | -5% |
| CGC | 0.3 | — | — | — | — | +7% | -55% | -26% |
| BIOA | 0.2 | — | — | — | — | +168% | — | -56% |
| SIGA | 0.2 | — | 2.0 | — | -9.1% | -70% | -21% | -30% |
| Median of these 10 | 4.5 | 2.0 | 15.6 | -4.5% | +15% | -9% | -7% |
; EV/Sales 1.8 vs. 2.0.
Growth vs. price
each dot a company · hover or tap for valuesEvolus, Inc. — questions
- What is Evolus, Inc.'s market cap?
- $463.0M.
- What is Evolus, Inc.'s price-to-sales ratio?
- 1.5.
Every figure on this page comes from Evolus, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.